Efficacy and safety of direct oral anticoagulants in patients with pulmonary thromboembolism

Abstract

Anticoagulant therapy is the treatment of any variant of pulmonary thromboembolism and patients in 100% of cases. In actual clinical practice, for the treatment and prevention, it is necessary to carry out regular control laboratory indicators, a constant dose adjustment, which can always be feasible for patients and it is not surprising to doctors when they independently discontinue treatment. The last decade was marked by the emergence of direct oral anticoagulants (DOAC) – factors determining Xa and direct thrombin inhibitor, which provide a predictable mechanism of action, the dosage regimen in standard dosages, no need for laboratory control and a minimum of food and drug interactions. In clinical practice, it is very important to try to balance the risks and benefits when choosing a new anticoagulant, which leads to a comparative analysis of the effectiveness and safety of all currently registered DOAC. This article is devoted to the analysis of the problems of safety and efficacy of anticoagulants, as well as their use over a long period of time. It should be understood that the large-scale studies convincingly prove that the effectiveness and safety of flights, however, should be recognized that patients with indications for thrombectomy reduce the rate of renal reaction with a glomerular rate of less than 30 ml/min. In this regard, the assessment of the actual efficacy and safety of the PAK also reveals risk factors for noncompliance in actual clinical practice, which are important not only with frequent dosing, but also with motivation, understanding, and socio-economic status of the pat ient.